KaliVir Immunotherapeutics, Inc.

KaliVir Immunotherapeutics, Inc. is a United States clinical-stage biotechnology company based in Pittsburgh, Pennsylvania, focused on the discovery and development of next-generation oncolytic viral immunotherapies for the treatment of cancer. The company describes its mission around a simple but ambitious idea — "multiple therapies, one virus" — reflecting a platform strategy in which a single engineered viral backbone can be adapted to generate multiple distinct therapeutic programs targeting different tumor types and treatment settings. KaliVir's core technology is its Novel Vaccinia Enhanced Template (VET) oncolytic platform. Oncolytic viruses are designed to selectively infect and destroy cancer cells while sparing normal tissue, and to stimulate an immune response against the tumor. KaliVir's VET platform is built on an engineered vaccinia virus backbone, which the company presents as a versatile chassis for arming with therapeutic payloads and for systemic or local delivery. The company's pipeline is therefore best understood as a family of product candidates derived from one platform rather than a single drug. As a clinical-stage company, KaliVir's activities center on research, preclinical development, and early clinical evaluation of its candidates, alongside the financing and partnership work typical of the sector. The company has raised venture financing, including a Series A extension round announced in August 2026, and it communicates with investors and the scientific community through news releases and presentations, such as those highlighting its VET oncolytic platform. KaliVir is privately held and operates primarily in the United States, with its corporate and research base in Pittsburgh. Its positioning is that of an innovative platform company in the immuno-oncology field, competing in the broader oncolytic virus and cancer immunotherapy space where differentiation rests on the engineering of the viral vector, the ability to deliver multiple payloads, and the potential to combine with other immunotherapies.

KaliVir Immunotherapeutics, Inc. is a privately held, clinical-stage biotechnology company located in Pittsburgh, Pennsylvania, in the United States. It was established to develop oncolytic viral immunotherapies — treatments that use engineered viruses to selectively attack cancer cells and to provoke an immune response against tumors. The company's public identity is organized around a platform concept rather than a single drug. Its website presents the tagline "multiple therapies, one virus," signaling that KaliVir builds a family of therapeutic candidates from one engineered viral backbone. That backbone is the Novel Vaccinia Enhanced Template (VET) oncolytic platform, which the company highlights in its investor and scientific presentations. Vaccinia virus is a well-studied vector in the immunotherapy field, and KaliVir's approach is to enhance and template it so that it can carry therapeutic payloads and be used across multiple programs. Because KaliVir is a clinical-stage company, much of its history is a record of platform development, pipeline advancement, and financing rather than commercial product launches. A visible milestone in its corporate timeline is the closing of a $14 million Series A extension financing, announced on August 19, 2026. Such a round is typically used to fund continued research, preclinical work, and early clinical trials, and it indicates ongoing investor support for the company's platform strategy. KaliVir operates primarily in the United States and maintains its base in Pittsburgh, a city with a substantial life-sciences and academic research community. The company communicates with stakeholders through its website, where it publishes news and events and makes presentations available, including materials on its VET oncolytic platform. As a private company, it does not report quarterly earnings or trade on a public exchange, and detailed financial and ownership information is not publicly disclosed in the available sources.

• KaliVir Immunotherapeutics announced the closing of a $14 million Series A extension financing.

Clinical-stage immuno-oncology platform company developing next-generation oncolytic viral immunotherapies built on a single engineered vaccinia virus backbone.

• Novel Vaccinia Enhanced Template (VET) oncolytic platform

  An engineered vaccinia virus-based oncolytic platform used to generate multiple cancer immunotherapy programs.

1. 1main - KaliVir Immunotherapeuticskalivir.com
2. 2Kalivir Immunotherapeutics, Inc. (United States) - Wikidatawikidata.org